E-LIB Suche - Ergebnisse für: Joseph P Eder

1

CEA-CD3 bispecific antibody cibisatamab with or without ate..:

Segal, Neil H. ; Melero, Ignacio ; Moreno, Victor...
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

NCI 7977: A Phase I Dose-Escalation Study of Intermittent O..:

Cecchini, Michael ; Walther, Zenta ; Wei, Wei...
Cancer Research Communications. 3 (2023) 6 - p. 1113-1117 , 2023

Link: https://doi.org/10.1158/..

3

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atez..:

Gomez-Roca, Carlos ; Cassier, Philippe ; Zamarin, Dmitriy...
Journal for ImmunoTherapy of Cancer. 10 (2022) 5 - p. e004076 , 2022

Link: https://doi.org/10.1136/..

4

Influence of tumor mutational burden, inflammatory gene exp..:

Haddad, Robert I ; Seiwert, Tanguy Y ; Chow, Laura Q M...
Journal for ImmunoTherapy of Cancer. 10 (2022) 2 - p. e003026 , 2022

Link: https://doi.org/10.1136/..

5

BRCA2 BRC missense variants disrupt RAD51-dependent DNA rep..:

Jimenez-Sainz, Judit ; Mathew, Joshua ; Moore, Gemma...
eLife. 11 (2022) - p. , 2022

Link: https://doi.org/10.7554/..

6

Skin puckering and edema during durvalumab therapy:

Olamiju, Brianna ; Odell, Ian ; Panse, Gauri..
JAAD Case Reports. 7 (2021) - p. 110-112 , 2021

Link: https://doi.org/10.1016/..

7

Preclinical investigations and a first-in-human phase I tri..:

Naing, Aung ; Eder, Joseph P ; Piha-Paul, Sarina A...
Journal for ImmunoTherapy of Cancer. 8 (2020) 2 - p. e000870 , 2020

Link: https://doi.org/10.1136/..

8

Efficacy and safety of pembrolizumab in recurrent/metastati..:

Mehra, Ranee ; Seiwert, Tanguy Y. ; Gupta, Shilpa...
British Journal of Cancer. 119 (2018) 2 - p. 153-159 , 2018

Link: https://doi.org/10.1038/..

9

Systemic and Mucocutaneous Reactions to Chemotherapy:

, In: Atlas of Diagnostic Oncology,

Eder, Joseph P. ; Skarin, Arthur T. - p. 721-736 , 2010

Link: https://doi.org/10.1016/..

10

Contributors:

, In: Atlas of Diagnostic Oncology,

van den Abbeele, Annick D. ; Abramson, Jeremy S. ; Anderson, Kenneth C.... - p. xi-xiv , 2010

Link: https://doi.org/10.1016/..

11

Phase I study of gefitinib, irinotecan, 5-fluorouracil and ..:

Meyerhardt, Jeffrey A. ; Clark, Jeffrey W. ; Supko, Jeffrey G....
Cancer Chemotherapy and Pharmacology. 60 (2007) 5 - p. 661-670 , 2007

Link: https://doi.org/10.1007/..

12

Safety, Pharmacokinetics, and Preliminary Antitumor Activit..:

Strumberg, Dirk ; Clark, Jeffrey W. ; Awada, Ahmad...
The Oncologist. 12 (2007) 4 - p. 426-437 , 2007

Link: https://doi.org/10.1634/..

13

Phase I clinical trial of bortezomib in combination with ge..:

Ryan, David P. ; Appleman, Leonard J. ; Lynch, Thomas...
Cancer. 107 (2006) 10 - p. 2482-2489 , 2006

Link: https://doi.org/10.1002/..

14

A Phase I study of bortezomib plus irinotecan in patients w..:

Ryan, David P. ; O'Neil, Bert H. ; Supko, Jeffrey G....
Cancer. 107 (2006) 11 - p. 2688-2697 , 2006

Link: https://doi.org/10.1002/..

15

Phase I dose‐escalation study of tezacitabine in combinatio..:

Bendell, Johanna C. ; Eder, Joseph P. ; Clark, Jeffrey W....
Cancer. 103 (2005) 9 - p. 1925-1931 , 2005

Link: https://doi.org/10.1002/..